Arbutus Biopharma Corp (ABUS): Total Liabilities
$18.04M
As of 2025-12-31
$15.29M
As of 2026-06-30
-32.5%
3-year compound annual growth
-12.5%
5-year compound annual growth
-19.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.04M | -47.5% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $34.34M | -10.5% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $38.38M | -34.5% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $58.57M | +67.1% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $35.05M | -0.2% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $35.11M | +7.1% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $32.79M | +18.5% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $27.67M | -49.4% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $54.69M | -25.0% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $72.91M | -55.7% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $164.61M | +446.1% | 2017-03-22, Balance as of period end |
| 2014-12-31 | $30.14M | +140.7% | 2016-03-09, Balance as of period end |
| 2013-12-31 | $12.52M | n/a | 2015-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| uniQure N.V. (QURE) | 2025-12-31 | $626.01M | +11.1% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
Compare ABUS, IRD, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗